東華大學圖書館 |

語系: 繁體中文

說明(常見問題)

回圖書館首頁

手機版館藏查詢

登入

回首頁

切換: 標籤 | MARC模式 | ISBD

Tumor Interferon Signaling Initiates...

Benci, Joseph L.

FindBook

Google Book

Amazon

博客來

Tumor Interferon Signaling Initiates and Sustains a Multigenic Resistance Program to Immune Checkpoint Blockade.

紀錄類型:	書目-電子資源 : Monograph/item
正題名/作者:	Tumor Interferon Signaling Initiates and Sustains a Multigenic Resistance Program to Immune Checkpoint Blockade./
作者:	Benci, Joseph L.
出版者:	Ann Arbor : ProQuest Dissertations & Theses, : 2017,
面頁冊數:	115 p.
附註:	Source: Dissertations Abstracts International, Volume: 79-04, Section: B.
Contained By:	Dissertations Abstracts International79-04B.
標題:	Molecular biology. -
電子資源:	http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=10284597
ISBN:	9780355181753

Tumor Interferon Signaling Initiates and Sustains a Multigenic Resistance Program to Immune Checkpoint Blockade.
Benci, Joseph L.

Tumor Interferon Signaling Initiates and Sustains a Multigenic Resistance Program to Immune Checkpoint Blockade. - Ann Arbor : ProQuest Dissertations & Theses, 2017 - 115 p.

Source: Dissertations Abstracts International, Volume: 79-04, Section: B.

Thesis (Ph.D.)--University of Pennsylvania, 2017.

This item is not available from ProQuest Dissertations & Theses.

Therapeutic blockade of the CTLA4 and/or PD1 immune checkpoint pathways has resulted in significant anti-tumor responses in broad variety of cancer types, but resistance is common. Using mouse models of metastatic melanoma and breast cancer in combination with CRISPR/Cas9 to selectively delete genes in our tumor cells, we demonstrate that prolonged interferon signaling orchestrates PDL1-dependent and PDL1-independent resistance to immune checkpoint blockade (ICB), and to combinations such as radiation plus anti-CTLA4. Furthermore, we show that this interferon driven resistance mechanism primarily occurs in ICB resistant tumors and not in ICB responsive tumors. Persistent type II interferon signaling allows tumors to acquire STAT1-related epigenomic changes and augments expression of interferon-stimulated genes and ligands for multiple T cell inhibitory receptors. Both type I and II interferons maintain this resistance program. Crippling the program genetically or pharmacologically interferes with multiple inhibitory pathways, and expands distinct T cell populations with improved anti-tumor functions despite expressing markers of severe exhaustion. Consequently, tumors resistant to multi-agent ICB are rendered responsive to ICB monotherapy. Finally, we observe that biomarkers for interferon-driven resistance associate with clinical progression after anti-PD1 therapy. Thus, the duration of tumor interferon signaling augments adaptive resistance and inhibition of the interferon response bypasses requirements for combinatorial ICB therapies.

ISBN: 9780355181753Subjects--Topical Terms:

517296
Molecular biology.

Tumor Interferon Signaling Initiates and Sustains a Multigenic Resistance Program to Immune Checkpoint Blockade.
LDR:02764nmm a2200349 4500 001 2206230
005 20190829083208.5
008 201008s2017 ||||||||||||||||| ||eng d
020 $a 9780355181753
035 $a (MiAaPQ)AAI10284597
035 $a (MiAaPQ)upenngdas:12805
035 $a AAI10284597
040 $a MiAaPQ $c MiAaPQ
100 1 $a Benci, Joseph L. $3 3433124
245 1 0 $a Tumor Interferon Signaling Initiates and Sustains a Multigenic Resistance Program to Immune Checkpoint Blockade.
260 1 $a Ann Arbor : $b ProQuest Dissertations & Theses, $c 2017
300 $a 115 p.
500 $a Source: Dissertations Abstracts International, Volume: 79-04, Section: B.
500 $a Publisher info.: Dissertation/Thesis.
500 $a Minn, Andy J.
502 $a Thesis (Ph.D.)--University of Pennsylvania, 2017.
506 $a This item is not available from ProQuest Dissertations & Theses.
506 $a This item must not be sold to any third party vendors.
520 $a Therapeutic blockade of the CTLA4 and/or PD1 immune checkpoint pathways has resulted in significant anti-tumor responses in broad variety of cancer types, but resistance is common. Using mouse models of metastatic melanoma and breast cancer in combination with CRISPR/Cas9 to selectively delete genes in our tumor cells, we demonstrate that prolonged interferon signaling orchestrates PDL1-dependent and PDL1-independent resistance to immune checkpoint blockade (ICB), and to combinations such as radiation plus anti-CTLA4. Furthermore, we show that this interferon driven resistance mechanism primarily occurs in ICB resistant tumors and not in ICB responsive tumors. Persistent type II interferon signaling allows tumors to acquire STAT1-related epigenomic changes and augments expression of interferon-stimulated genes and ligands for multiple T cell inhibitory receptors. Both type I and II interferons maintain this resistance program. Crippling the program genetically or pharmacologically interferes with multiple inhibitory pathways, and expands distinct T cell populations with improved anti-tumor functions despite expressing markers of severe exhaustion. Consequently, tumors resistant to multi-agent ICB are rendered responsive to ICB monotherapy. Finally, we observe that biomarkers for interferon-driven resistance associate with clinical progression after anti-PD1 therapy. Thus, the duration of tumor interferon signaling augments adaptive resistance and inhibition of the interferon response bypasses requirements for combinatorial ICB therapies.
590 $a School code: 0175.
650 4 $a Molecular biology. $3 517296
650 4 $a Biostatistics. $3 1002712
650 4 $a Cellular biology. $3 3172791
690 $a 0307
690 $a 0308
690 $a 0379
710 2 $a University of Pennsylvania. $b Cell and Molecular Biology. $3 2101694
773 0 $t Dissertations Abstracts International $g 79-04B.
790 $a 0175
791 $a Ph.D.
792 $a 2017
793 $a English
856 4 0 $u http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=10284597